Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Inclusion Criteria

• •Have pathologically confirmed diagnosis of resectable triple negative breast cancer (ASCO/CAP guidelines will be used to define triple negative breast cancer)
• •Must have measurable disease. Multi-centric disease is allowed. If patient has another lesion which is biopsied with ER/PR positive it will be Physician discretion for this eligibility criteria.
• •Prior therapy: No prior cytotoxic regimens are allowed for this malignancy. Participants may not have had prior chemotherapy, other targeted anticancer therapies, or prior radiation therapy to the ipsilateral breast for this malignancy. Prior bis-phosphonate therapy is allowed
• •Patient eligible for surgery as determined by patient's surgeon
• •Patient must have a lesion that amendable to biopsy, unless inaccessible and with PI approval
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2
• •Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• •Ability to swallow and retain oral medication
• •Ability to undergo magnetic resonance imaging (MRI)
• •Platelets \>= 100,000/uL
• •Hemoglobin \>= 9 g/dL
• •Absolute neutrophil count (ANC) \>= 1500/uL
• •Total bilirubin =\< institutional upper limit of normal (ULN)
• •Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and ALT (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 X institutional upper limit of normal (ULN)
• •Creatinine \< ULN OR creatinine clearance \>= 50 mL/min per Cockcroft-Gault equation for patients with creatinine levels greater than ULN
• •Left ventricular ejection fraction (LVEF) \>= 55%; if LVEF is \< 55% and patient is otherwise study-eligible, the principal investigator (PI) will discuss with cardiologist if patient is eligible to receive doxorubicin and participate in study
• •Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
• •Participants on this study will be counseled on and are willing to use adequate contraceptive methods